Exchange: NASDAQ·Updated 07:34 PM EDT
TXG logo

TXG10x Genomics Inc - Ordinary Shares - Class A

$46.55
$0.15
(0.32%)
Today
Closed $47.05
$0.4978
(1.06%)
After Hours
EarningsAug 6
Mkt Cap$5.99B
Vol2.82M
News
all
press releases
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 PR Newswire PLEASANTON, Calif., July 15, 2026 PLEASANTON, Calif., July 15, 2026 /PRNewswire/ --10x Genomics, Inc.(Nasdaq: TXG), the life...
PR Newswire
More News
Top 3 Health Care Stocks That May Implode This Month
Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.read more...
Benzinga
American Well (AMWL) Moves 9.4% Higher: Will This Strength Last?
American Well (AMWL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
Zacks
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies...
PR Newswire
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
Zacks
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group PR Newswire PLEASANTON, Calif., June 9, 2026 Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026...
PR Newswire
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
Key PointsCEO Serge Saxonov sold 28,893 shares for a total of ~$709,000 across two open-market transactions completed by May 26, 2026...
Nasdaq News: Markets
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
Key PointsQuantedge Capital added 212,600 shares of 10x Genomics in the first quarter; the estimated transaction value was $4.25 million based on quarterly average pricing...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.